A new gemcitabine intravesical system appears to lower the likelihood of radical cystectomy in high-risk, BCG-unresponsive non–muscle invasive bladder cancer. Published on Onclive, the article highlights how this therapy could significantly impact patient care moving forward.

CG Oncology, a small biotech firm rivaling Johnson & Johnson, saw its stock soar 44% following promising clinical trial results for its bladder cancer drug. The breakthrough has drawn significant investor attention and could signal a shift in cancer treatment options.